Use of Novel Therapies in Endometrial Cancer: Update for Managed Care | PTCE Pharmacy Connect
Accreditation and support statement:
· PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
· This activity is supported by educational grant from GlaxoSmithKline.
Objectives
• Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer.
• Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.
Learn more about your ad choices. Visit megaphone.fm/adchoices
· PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
· This activity is supported by educational grant from GlaxoSmithKline.
Objectives
• Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer.
• Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Activity